https://www.businesswire.com/news/home/20180723005574/en/ > LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 23, 2018--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that researchers have uncovered novel links between several blood-based biomarkers and the diagnosis of brain injuries and chronic neuropsychological symptoms in military personnel and veterans, using its flagship Simoa technology. With unprecedented levels of sensitivity, Simoa is giving researchers the ability to achieve never-before-seen insights into the diagnosis of brain injuries and the relationship between these conditions and PTSD in our military. > According to the Defense and Veterans Brain Injury Center, nearly 800,000 veterans have been diagnosed with traumatic brain injuries (TBIs) since 2000 and more than 80 percent are considered to be mild (mTBI). Previously, researchers lacked the sensitivity needed to examine mTBIs, which often do not present symptoms and frequently go undiagnosed, potentially leading to neurological complications later in life.